Celaid Therapeutics is a Japan-based biotechnology company, which has developed a platform technology to efficiently expand hematopoietic stem cells ex vivo without choosing its origins, including bone marrow, cord blood, or peripheral blood. By using the novel technology, we are developing a cell therapy product that brings HSC transplantation to the next level and helps patients with blood disorders. Our technology has many potential applications including gene/cell therapy that utilize gene editing on HSC.
Our mission is to improve QOL of patients, their families, and HSC donors all over the world.
Company Details
- Employees
- 14
- Founded
- 2020
- Address
- 7-3-1, Hongo, Utokyo Enterpreneur Lab./south Clinical Research Bldg.,japan
- Industry
- Biotechnology
- Website
- https://celaidtx.com/
- HQ
- Bunkyo-ku, Tokyo
Celaid Therapeutics Questions
Celaid Therapeutics's website is https://celaidtx.com/
Celaid Therapeutics's LinkedIn profile is https://jp.linkedin.com/company/celaid-therapeutics
Celaid Therapeutics has
14 employees.
View email and phone details for 14
employees at Celaid Therapeutics.
Celaid Therapeutics's industry is
Biotechnology
Celaid Therapeutics's top competitors are
Stemsight,
C4u Corporation,
Autolus Therapeutics,
Lquom, Inc.,
Novita Pharmaceuticals,
Inso Biosciences,
Digireha, Inc.,
Purmx Therapeutics,inc.,
Sixpeaks Bio,
Bipsee.
Celaid Therapeutics's categories are Biotechnology
Celaid Therapeutics's founding year is 2020
